Quantcast
Home > Quotes > AKAO
AKAO

Achaogen, Inc. Common Stock (AKAO) Quote & Summary Data

$1.8
*  
0.13
6.74%
Get AKAO Alerts
*Delayed - data as of Nov. 14, 2018  -  Find a broker to begin trading AKAO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    AKAO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.94 / $ 1.70
Share Volume
1,202,417
50 Day Avg. Daily Volume
833,047
Previous Close
$ 1.93
52 Week High / Low
$ 15 / $ 1.745
Market Cap
83,015,714
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
1,202,417
50 Day Avg. Daily Volume:
833,047

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.26

Trading Range

The current last sale of $1.80 is 3.15% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.94 $ 15
 Low: $ 1.70 $ 1.745

Company Description (as filed with the SEC)

We are a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multi-drug resistant ("MDR") gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae ("CRE"). In 2013, the Centers for Disease Control and Prevention ("CDC") identified CRE as a "nightmare bacteria" and an immediate public health threat that requires "urgent and aggressive action" and in 2017 the World Health Organization ("WHO") identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics.  ... More ...  


Risk Grade

Where does AKAO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.94
Open Date:
Nov. 14, 2018
Close Price:
$ 1.80
Close Date:
Nov. 14, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x